Sequenom
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sequenom sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Sequenom: 26 sponsored US clinical trials, 6 recruiting.
Sequenom sponsors 26 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 17 completed. The most-studied condition in this pipeline is Down Syndrome, with 3 trials.
Top-decile sponsor footprint
Sequenom ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
NCT07543757
Non-Invasive Preeclampsia Screening and Biobank
NCT06643741
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
NCT04595201
Compliant Analysis of Patient Samples and Data
NCT04364503
Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
NCT02586389
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
NCT01429389
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
NCT03631225
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
NCT06008457
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test
NCT03810144
Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies
NCT02226315
Development of a NIPTT for Detecting Copy Number Variations
NCT04774640
Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test
NCT01835483
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
NCT01880788
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
NCT01682382
Genetic Load and Phenotype in Aggressive AMD
NCT01650948
Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients
NCT01644513
Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies
NCT01597063
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies
NCT01555346
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
NCT01052688
Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
NCT00971334
Evaluation of a Noninvasive Fetal RHD Genotyping Test
NCT01054716
Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies
NCT01021085
A Noninvasive Test for Fetal RHD Genotype
NCT00871195
Non-Invasive Screening for Fetal Aneuploidy
NCT00847990
Development of a Fetal Sex Assay From Maternal Whole Blood
NCT00970047
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
NCT00770458
What is open in the Sequenom pipeline
6 recruiting of 26 indexed (23% open); 17 completed (65%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Down Syndrome (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sequenom: open-pipeline peers nationwide
Peers matched on 26 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Sequenom sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- Aldeyra Therapeutics · 26 trials · 4% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sumitomo Pharma Switzerland · 23% recruiting · 13 trials
Related
What to do with this Sequenom page
26 registered trials is a research-attention snapshot, not an endorsement of Sequenom or any single study.
- 6 of Sequenom's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Down Syndrome is the condition Sequenom studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Down Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sequenom pipeline card: 26 registered trials from official public datasets.Report a data error.